A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Clinical trial NCT03886662 · RECRUITING
Trial details
- NCT number
- NCT03886662
- Sponsor
- Lixte Biotechnology Holdings, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-01
- Primary completion
- 2021-05-01
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.